The TCL1 family of oncoproteins: co-activators of transformation.
The T-cell leukaemia/lymphoma 1 (TCL1)-family oncoproteins augment AKT signal transduction and enhance cell proliferation and survival. Chromosome rearrangements, faulty developmental silencing and Epstein-Barr virus infection appear to dysregulate the expression of TCL1-family genes, provoking several important types of lymphocyte cancer. A key role for TCL1 proteins in cell transformation has been established in studies of transgenic mouse models, which develop a unique spectrum of T- and B-cell malignancies. How TCL1 proteins are regulated and dysregulated, how they promote transformation and the potential for therapies modelled on TCL1 interactions have important implications for understanding and treating lymphocyte cancers.
Teitell
Michael A
MA
Department of Pathology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 675 Charles Young Drive South, 4-762 MacDonald Research Laboratories, Los Angeles, California 90095-1732, USA. mteitell@ucla.edu
D000818:Animals; D006801:Humans; D007938:Leukemia / Q000503:physiopathology*; D008223:Lymphoma / Q000503:physiopathology*; D051379:Mice; D023421:Models, Animal; D015513:Oncogene Proteins / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D015534:Trans-Activators / Q000502:physiology
D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human; D015534:Trans-Activators